Table 1.
Baseline characteristics of SjögrenSER patients according to the severity in the dry eye
| Variables | Dry eye not severe (n = 32) | Severe/very severe dry eye (n = 378) | p |
|---|---|---|---|
| Age at diagnosis, mean (SD) | 49.33 (13.9) | 50.56 (12.7) | 0.195 |
| Sex, women n (%) | 57 (96.6) | 359 (95.0) | 0.585 |
| Index | |||
| ESSPRI, mean (SD) | 5.20 (2.5) | 5.28 (2.3) | 0.980 |
| ESSDAI, mean (SD) | 5 (7) | 5 (5) | 0.854 |
| Systemic manifestations | |||
| Inflammatory articular involvement n (%) | 41 (69.5) | 312 (82.5) | 0.028* |
| Pulmonar involvement n (%) | 6 (10.3) | 37 (9.8) | 0.895 |
| Renal involvement n (%) | 6 (10.3) | 33 (8.7) | 0.688 |
| Central nervous system involvement n (%) | 5 (8.6) | 29 (7.7) | 0.802 |
| Glandular inflammation n (%) | 21 (35.6) | 121 (32.0) | 0.585 |
| Peripheral nervous system involvement n (%) | 5 (8.6) | 34 (9.0) | 0.926 |
| Digestive involvement n (%) | 11 (18.6) | 48 (12.7) | 0.214 |
| Hematologic involvement n (%) | 31 (52.5) | 213 (56.3) | 0.584 |
| Pathological labial salivary gland biopsy (focus score ≥ 1) n (%) | 26 (44.1) | 107 (28.3) | 0.014* |
| Analysis | |||
| ANA + n (%) | 58 (98.3) | 366 (96.8) | 0.534 |
| RF + n (%) | 39 (72.2) | 245 (65.7) | 0.341 |
| AntiRo + n (%) | 58 (98.3) | 351 (92.9) | 0.112 |
| AntiLa + n (%) | 42 (71.2) | 251 (66.4) | 0.467 |
* p < 0.05